Work

27LBA Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in combination

Year: 2015

Type: article

Source: European Journal of Cancer

DOI: 10.1016/s0959-8049(15)30076-9

Authors: H.T. Arkenau, M. Voskoboynik, J. Infante, A. Brenner, M. Patel, E. Borazanci, G. Falchook, L.R. Molife, S. Pant, E. Dean, L. Pelosof, S. Jones, C. Rubino, W. McCulloch, V. Zhukova-Harrill, G. Kemble, M. O'Farrell, H. Burris

Language: English

Topic: Cancer, Lipids, and Metabolism

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2209500407

FWCI: 0.294

Cites:

Cited by: 6

Related to: 10